Elagolix/estradiol/norethisterone acetate: Difference between revisions

'''Elagolix/estradiol/norethindrone acetate''', sold under the brand name '''Oriahnn''', is a [[fixed-dose combination]] medication used to treat heavy [[menstrual bleeding]] associated with uterine [[leiomyoma]]s ([[Uterine fibroid|fibroids]]) in premenopausal women.<ref name="Oriahnn FDA label" /><ref name="FDA PR">{{cite press release | title=FDA Approves New Option to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 May 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-option-treat-heavy-menstrual-bleeding-associated-fibroids-women | access-date=29 May 2020}} {{PD-notice}}</ref><ref name="Ali_2021">{{cite journal | vauthors = Ali M, Sara AR, Al Hendy A | title = Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women | journal = Expert Review of Clinical Pharmacology | volume = 14 | issue = 4 | pages = 427–437 | date = April 2021 | pmid = 33682578 | doi = 10.1080/17512433.2021.1900726 }}</ref> It contains [[elagolix]], a gonadotropin-releasing hormone (GnRH) receptor antagonist, [[estradiol]], an [[Estrogen (medication)|estrogen]], and [[norethindrone acetate]], a [[Progestogen (medication)|progestin]].<ref name="Oriahnn FDA label" /><ref name="FDA PR" /> It is taken [[Oral administration|by mouth]].<ref name="Oriahnn FDA label" /><ref name="FDA PR" /> Oriahnn is co-packaged as a combination of elagolix/estradiol/norethindrone acetate capsules with elagolix capsules.<ref name="Oriahnn FDA label" />